Ceradyne Inc.

Wedbush Securities has downgraded Ceradyne (NASDAQ: CRDN) from Outperform to Neutral and has lowered the price target from $54 to $42.

According to Benchmark, Ceradyne (NASDAQ: CRDN) price target is increased from $52 to $56. Benchmark reported that it walked away from several days of investor marketing with Ceradyne's management last week more impressed with its transformation from defense (>70% of sales in 2007) to a multi-...

Benchmark has raised the price target on Ceradyne (NASDAQ: CRDN) from $52 to $56 and maintains its Buy rating.

Benchmark has reported on Ceradyne's (NASDAQ: CRDN) FY11 outlook after a helmet testing issue. According to Benchmark, "Some of Ceradyne's Enhanced Combat Helmets (ECH) failed the military's First Article Test (FAT), according to an article on military.com on Friday. We believe this testing issue...